Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma.
Metro G, Signorelli D, Pizzutilo EG, Giannetta L, Cerea G, Garaffa M, Friedlaender A, Addeo A, Mandarano M, Bellezza G, Roila F. Metro G, et al. Hum Vaccin Immunother. 2021 Sep 2;17(9):2972-2980. doi: 10.1080/21645515.2021.1917933. Epub 2021 May 18. Hum Vaccin Immunother. 2021. PMID: 34003722 Free PMC article.
Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G, Chiari R, Bennati C, Cenci M, Ricciuti B, Puma F, Flacco A, Rebonato A, Giannarelli D, Ludovini V, Bellezza G, Ferolla P, Minotti V, Crinò L. Metro G, et al. Clin Lung Cancer. 2014 Jan;15(1):86-92. doi: 10.1016/j.cllc.2013.08.002. Epub 2013 Oct 17. Clin Lung Cancer. 2014. PMID: 24139827
Future options for ALK-positive non-small cell lung cancer.
Iacono D, Chiari R, Metro G, Bennati C, Bellezza G, Cenci M, Ricciuti B, Sidoni A, Baglivo S, Minotti V, Crinò L. Iacono D, et al. Among authors: metro g. Lung Cancer. 2015 Mar;87(3):211-9. doi: 10.1016/j.lungcan.2014.12.017. Epub 2015 Jan 3. Lung Cancer. 2015. PMID: 25601484 Review.
Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis.
Chiari R, Metro G, Iacono D, Bellezza G, Rebonato A, Dubini A, Sperduti I, Bennati C, Paglialunga L, Burgio MA, Baglivo S, Giusti R, Minotti V, Delmonte A, Crinò L. Chiari R, et al. Among authors: metro g. Lung Cancer. 2015 Nov;90(2):255-60. doi: 10.1016/j.lungcan.2015.09.009. Epub 2015 Sep 14. Lung Cancer. 2015. PMID: 26395848
Gene identification for risk of relapse in stage I lung adenocarcinoma patients: a combined methodology of gene expression profiling and computational gene network analysis.
Ludovini V, Bianconi F, Siggillino A, Piobbico D, Vannucci J, Metro G, Chiari R, Bellezza G, Puma F, Della Fazia MA, Servillo G, Crinò L. Ludovini V, et al. Among authors: metro g. Oncotarget. 2016 May 24;7(21):30561-74. doi: 10.18632/oncotarget.8723. Oncotarget. 2016. PMID: 27081700 Free PMC article.
The safety of nivolumab for the treatment of advanced non-small cell lung cancer.
Metro G, Ricciuti B, Brambilla M, Baglivo S, Soli I, Minenza E, Leonardi GC, D'arpino A, Colabrese D, Tazza M, Zicari D, Minotti V, Chiari R. Metro G, et al. Expert Opin Drug Saf. 2017 Jan;16(1):101-109. doi: 10.1080/14740338.2017.1267725. Epub 2016 Dec 11. Expert Opin Drug Saf. 2017. PMID: 27910704 Review.
183 results